Serigne Lo - Concepedia

Author

Serigne Lo

Also Known As

Heritier, Stephane, Lo, S., Lo, Serigne, Lo, Serigne N., Long, Georgina V., Lô, Serigne Ndame, N Foster, S Lo, S N Lo, S. Lo

597

Publications

14.7K

Citations

H-Index

145

Concepts

All Affiliations

The University of Sydney Melanoma Institute Australia Royal Prince Alfred Hospital Royal North Shore Hospital The George Institute for Global Health

About

Serigne Lo is an author at The University of Sydney specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	61	4.4K
2	Health Sciences	15	19	727
3	Public Health	4	4	116
4	Education	1	1	12
5	Engineering	1	1	15

Serigne Lo

167

Publications

12.1K

Citations

H-Index

Page 1

	Year	Citations
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy Tuba N. Gide, Camelia Quek, Alexander M. Menzies, Cancer Cell	2019	980
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study Georgina V. Long, Victoria Atkinson, Serigne Lo, The Lancet Oncology Neuro-oncologyMelanoma Brain MetastasesMedicineMelanomaPathology	2018	975
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer Jeanne Tie, Joshua D. Cohen, Kamel Lahouel, New England Journal of Medicine	2022	884
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) Alexander M. Menzies, Rodabe N. Amaria, Elisa A. Rozeman, Nature Medicine Surgical OncologyNeoadjuvant TherapyMedicineMelanomaPathology	2021	408
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma Jenny Lee, Georgina V. Long, Stephanie Boyd, Annals of Oncology Anti-pd1 AntibodiesCancer ImmunosurveillanceOncologyTumour DnaMedicine	2017	319
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets Felicity Newell, Yan Kong, James S. Wilmott, Nature Communications	2019	319
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies Jenny Lee, Georgina V. Long, Alexander M. Menzies, JAMA Oncology	2018	305
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma Ricardo E. Vilain, Alexander M. Menzies, James S. Wilmott, Clinical Cancer Research	2017	243
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, The Lancet Oncology OncologyAnti-pd-1 TherapyMelanomaImmunologyClinical Trials	2021	201
A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults* David Gattas, Dorrilyn Rajbhandari, Celia Bradford, Critical Care Medicine	2015	191

Page 1